【10月14日IPO雷达】禾元生物申购

Core Viewpoint - The company He Yuan Bio is set to launch an IPO on the Sci-Tech Innovation Board with a total market value of 7.789 billion yuan and an issue price of 29.06 yuan per share [2]. Group 1: Company Overview - He Yuan Bio utilizes a rice endosperm cell bioreactor technology platform (OryzPur) for efficient recombinant protein production [2]. - The company is a pioneer in China in using rice endosperm cell bioreactors for drug production [2]. - The main business composition includes 80.64% from recombinant human albumin (pharmaceutical excipients, research reagents) and 19.36% from other sources [2]. Group 2: Financial Performance - The company reported a net profit of 25.22 million yuan in the last three years, with a projected increase of 3.92% in 2024 [3]. - Revenue for 2023 reached 24.26 million yuan, marking an 81.08% increase compared to the previous year [3]. - The net profit for 2022 was 13.40 million yuan, reflecting a decrease of 47.49% from 2021 [3]. Group 3: Fundraising Purpose - The funds raised will be directed towards the construction of a recombinant human albumin industrialization base and new drug research and development projects [3].